Published in final edited form as:

Clin Cancer Res. 2008 June 15; 14(12): 3906–3915. doi:10.1158/1078-0432.CCR-08-0366.

Phase II study of dasatinib in Philadelphia chromosome-negative acute and chronic myeloid diseases, including systemic mastocytosis

Srdan Verstovsek¹, Ayalew Tefferi², Jorge Cortes¹, Susan O'Brien¹, Guillermo Garcia-Manero¹, Animesh Pardanani², Cem Akin³, Stefan Faderl¹, Taghi Manshouri¹, Deborah Thomas¹, and Hagop Kantarjian¹

¹Leukemia Department, MD Anderson Cancer Center, Houston, TX, USA

²Division of Hematology, Mayo Clinic College of Medicine, Rochester, MN, USA

³University of Michigan, Ann Arbor, Michigan, USA

Abstract

Molecular characterization of Philadelphia chromosome-negative (Ph⁻) chronic myeloproliferative disorders, such as systemic mastocytosis (SM), has provided a clear rationale for investigating novel targeted therapies. The tyrosine kinase (TK) inhibitor dasatinib is 325-fold more potent against Bcr-Abl TK than imatinib *in vitro*, significantly inhibiting wild-type KIT and PDGFR-B TKs, and is active against cells carrying the mutant KIT-D816V gene. In this phase 2, open-label study, the efficacy of dasatinib (140 mg/day) was investigated in 67 patients with various Ph⁻ myeloid disorders, including SM (N=33; 28 KIT-D816V positive).

The overall response rate to dasatinib in patients with SM was 33%. Only two patients, one with SM-myelofibrosis and one with SM-chronic eosinophilic leukemia, achieved complete response (elimination of mastocytosis) lasting for 5 and 16 months, respectively. Both patients were negative for KIT-D816V mutation, had low tryptase levels, abnormal WBC counts, and anemia, and had failed prior therapy with erythropoietin. Additional 9 SM patients had symptomatic response, lasting 3 to 18+ months.

Complete responses were achieved in two other patients (acute myeloid leukemia, hypereosinophilic syndrome). No responses were observed among patients with myelodysplastic syndromes and primary myelofibrosis. The majority of adverse events were grade 1/2. These data show that dasatinib may benefit a selected group of SM patients, primarily by improving their symptoms.

Keywords

Dasatinib; systemic mastocytosis; hypereosinophilic syndrome; primary myelofibrosis; myelodysplastic syndrome; acute myeloid leukemia

Introduction

Despite clinical progress in leukemia therapy, notably the introduction of BCR-ABL-targeted therapies for Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML),¹ most adult patients with advanced or refractory myeloid malignancies still die from their disease. For example, no generally effective therapy has been established for Ph-negative (Ph-) chronic myeloproliferative diseases (CMPD).² Therefore, there is an urgent need to identify new targeted treatments for a range of potentially life-threatening myeloid diseases, including acute myeloid leukemia (AML), myelodysplastic syndromes (MDS), primary myelofibrosis (PMF), hypereosinophilic syndrome (HES), chronic eosinophilic leukemia (CEL), and systemic mastocytosis (SM).

Four main subcategories of SM are described by the World Health Organization (WHO) classification system for mast cell diseases³: indolent SM (ISM), SM with an associated clonal hematological non-mast cell disorder (SM-AHNMD), aggressive SM (ASM), and mast cell leukemia (MCL). Although standard cytoreductive therapies for SM may provide symptomatic improvements, responses are transient and the overall prognosis, which is particularly poor for patients with ASM, SM-AHNMD, and MCL, remains unchanged by treatment.⁴

Impetus for the clinical investigation of novel targeted agents for the treatment of CMPD has been provided by advances in molecular characterization of these diverse diseases. KIT is a 145 kDa transmembrane class III receptor tyrosine kinase (TK)⁵ required for human mast cell growth, differentiation, and functional activation.⁶⁷ Gain-of-function point mutations in the KIT kinase domain result in ligand-independent constitutive activation of KIT signaling, leading to uncontrolled mast cell proliferation and resistance to apoptosis.⁸ One of these KIT mutations (D816V) is present in more than 90% of patients with SM⁹¹⁰¹¹ and mutated KIT has also been described in patients with AML.¹² Additional genetic abnormalities have been identified in patients with SM-AHNMD,¹³¹⁴ in whom an associated CEL may be linked to the FIP1L1-platelet derived growth factor receptor (PDGFR) α fusion gene.^{13,15,16,17} A large body of data supports a role for PDGFR TKs in the pathophysiology of several subtypes of MDS and MPD.¹⁸ Mutated genes in molecularly-defined CEL include those encoding for PDGFR α and - β and fibroblast growth factor receptor 1 (FGFR1).

In preclinical studies, the TK inhibitor imatinib mesylate (Gleevec®, Novartis, New Jersey, USA) inhibited, KIT, FGFR, and PDGFR, suggesting that it has a potential role in certain hematologic neoplasms expressing these kinases.¹⁹²⁰²¹ Imatinib has demonstrated activity against neoplastic mast cells exhibiting wild type KIT and the spontaneously immortalized human mast cell line HMC-1.1 expressing mutant KIT-V560G, but it failed to inhibit HMC-1.2 cells expressing the mutant KIT-D816V.²²²³ Imatinib has also been investigated in several clinical studies of patients with CMPD, including SM,²⁴²⁵ HES/CEL,²⁶²⁷²⁸ and PMF.²⁹³⁰ Durable hematologic and cytogenetic responses were achieved with imatinib in a recent study of 12 patients with PDGFR β fusion-positive, BCR-ABL-negative CMPD.³¹ Furthermore, imatinib 100 mg/day is the treatment of choice for FIP1L1-PDGFR α -positive SM-CEL or other clonal eosinophilia, and induces a complete hematologic and molecular remission in almost all treated patients.¹⁵³² However, in FIP1L1-PDGFR α -negative HES,

treatment with imatinib is unlikely to produce durable remissions.¹⁵ Similarly, therapy with imatinib does not usually benefit patients with SM in whom imatinib-sensitive molecular markers, such as FIP1L1-PDGFR α , are absent,²⁴³³ and imatinib is not indicated for those with KIT-D816V mutation. Because of the efficacy limitations of standard cytoreductive therapies, several new TK inhibitors and other novel therapeutic agents are under active clinical investigation in patients with CMPD.³⁴³⁵³⁶

Dasatinib (SPRYCEL®, Bristol-Myers Squibb, New York, USA) is a dual Src/Abl kinase inhibitor with demonstrated clinical activity in all stages of Ph+ CML, after the failure of imatinib.³⁷³⁸³⁹⁴⁰ Dasatinib is approved for the treatment of Ph+ CML and Ph+ acute lymphoblastic leukemia in patients resistant or intolerant to imatinib. Dasatinib is 325-fold more potent against Bcr-Abl than imatinib *in vitro*,⁴¹ and has significant inhibitory activity against wild-type KIT (IC50 5 nM) and PDGFR β (IC50 28 nM).⁴² Preclinical studies have shown that dasatinib potently inhibits both the growth of HMC-1.2 cells carrying the mutant KIT-D816V⁴³ and primary mast cells with KIT-D816V mutation obtained from patients with SM.⁴⁴ These preclinical studies suggested that dasatinib might be clinically effective in patients with SM that in more than 90% of cases carry this KIT mutation.

In this phase 2, open-label study, the efficacy of dasatinib was investigated in patients with Ph- myeloid diseases, potentially expressing KIT and PDGFR. The primary objective was to determine the objective response rate to dasatinib according to disease-specific response criteria. The secondary objective was to evaluate the duration of response.

Patients, materials, and methods

Patients

Patients included in the study were aged ≥ 18 years and had a confirmed diagnosis of one of the following Ph- acute or chronic myeloid diseases: (1) SM; (2) KIT positive AML or MDS (10% or more bone marrow or peripheral blood mononuclear cells positive by flow for CD117), excluding acute promyelocytic leukemia (specifically: refractory-relapsed AML or MDS, including those who failed to achieve complete response after the first cycle of induction, second or subsequent therapy, or newly diagnosed AML or MDS patients over 60 years of age with karyotype other than t(15:17), inv16, t(8:21), who did not want to receive chemotherapy) or chronic myelomonocytic leukemia (CMML), a subtype of MDS; (3) HES/CEL; (4) PMF. All patients were required to have serum bilirubin level <2 mg%, serum creatinine level <2 mg% (unless the abnormality was considered by the investigator to be due to hematologic malignancy), Eastern Cooperative Oncology Group (ECOG) performance status (PS) ≤ 3 , and adequate cardiac status (New York Heart Association grade ≤ 3). Patients with cardiac symptoms (uncontrolled angina within 3 months, congenital long QT syndrome, prolonged QTc interval on pre-entry electrocardiogram >450 msec) on both the Fridericia and Bazett's correction, clinically significant ventricular arrhythmias such as ventricular tachycardia, ventricular fibrillation, or Torsades de pointes), uncontrolled hypertension, a history of significant bleeding disorder unrelated to cancer, acquired bleeding disorder within one year, and patients receiving drugs associated with a risk of Torsades de Pointes were not eligible. Women of childbearing potential were required to

have a negative pregnancy test and to use an effective contraceptive method. There were no exclusions of women or minorities based on the study objectives.

The protocol was approved by the research ethics board of the University of Texas M.D. Anderson Cancer Center; this was a single center study. Written informed consent was obtained, according to institutional policy and the Declaration of Helsinki.

Treatment protocol

Dasatinib was administered orally at a starting dose of 70 mg twice daily, or 140 mg as a single daily dose. Treatment was administered at the same dose until disease progression or the occurrence of adverse events necessitating dose reduction or discontinuation. Adverse events were assessed and graded using the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) Version 3.

The dose of dasatinib could be increased by one level in patients showing evidence of progressive disease or no response after 8 weeks (Table 1). Treatment was interrupted for CTC grade 2 non-hematologic toxicity (except alopecia and fatigue) and restarted at the original dose after resolution of the adverse event to grade 1 or return to baseline. The dose could be further reduced by one level each time the same adverse event recurred (maximum of three reductions). A similar dose modification scheme was used when grade 3 non-hematologic toxicity occurred, except that the dose was reduced by one level on restarting therapy after the first occurrence of the adverse event. Dasatinib was generally discontinued in cases of grade 4 non-hematologic toxicity, although continuation with a dose reduction of at least one level was permitted at the investigators' discretion. Treatment was not modified or interrupted if neutropenia occurred during the first 14 days of treatment. Thereafter, if grade 4 neutropenia ($ANC < 0.5 \times 10^9/L$) occurred and marrow cellularity was $< 10\%$, or $> 10\%$ and neutropenia persisted for 4 weeks, treatment was interrupted and restarted at the original dose after neutrophil recovery to $> 1.0 \times 10^9/L$. Doses were subsequently reduced by one level each time grade 4 neutropenia recurred. Dose modification was not applied in patients with AML and MDS when myelosuppression was attributable to disease.

No other therapies for the treatment of myeloid diseases were permitted except for anagrelide and hydroxyurea for initial reduction of platelet and WBC counts, and hematopoietic growth factors at the investigators' discretion. The administration of drugs that inhibit platelet function, prolong QT interval, or inhibit/induce CYP3A4 were prohibited or restricted.

Response assessment

Evaluation of patients during the study period included, at minimum, complete blood counts weekly for 4 weeks, then every 2–4 weeks; serum chemistry every 2 weeks for 2 weeks, then every month; bone marrow biopsy and/or aspirate every 1–3 months; an electrocardiogram between days 4 and 8 of cycle 1.

Patients were evaluated for response after a minimum of three treatment cycles (one cycle was defined as $28 \text{ days} \pm 7 \text{ days}$). Patients had to be off any supportive care therapy,

including hydroxyurea, anagrelide, transfusions, or hematopoietic growth factors, for a response to be documented. All patients who received any dasatinib were considered evaluable for efficacy analyses according to the response criteria shown in Table 2.

Patients were removed from the study if they developed progressive disease with no response to therapy despite increases of treatment doses or duration, experienced unacceptable toxicity despite dose reduction, did not comply with the treatment schedule, withdrew their consent, or died.

Statistical considerations

The primary objective of the study was to determine the activity of dasatinib. The response rate and duration of response were measured. Because dasatinib has a unique mode of action, a response rate as low as 10% was deemed to be of interest. The study sample size determination was based a minimum-maximum total of 14–25 patients in each diagnostic group, yielding an 82% posterior credibility interval for probability of response of width approximately 0.16. For each diagnostic group, an interim analysis was planned after 14 patients had been evaluated. In SM diagnostic group, after the accrual of first 24 patients, the protocol was modified to allow the accrual of an additional nine patients, treated with the alternative dose/schedule of dasatinib.

Results

Patient characteristics

The characteristics of 67 patients included in the study are detailed in Table 3. Patients with SM comprised approximately half (49%) of the study population. The next most common diagnosis was PMF (16%), followed by AML (13%), HES/CEL (12%), and MDS/CMML (10%).

Among the group with SM, there were nine patients with ASM, 18 with ISM, and six with SM-AHNMD, including one case each of CEL, PMF, MDS/MPD, and three cases of CMML. Sixteen patients had not received prior treatment for SM. KIT-D816V mutation status was positive in 28 patients, negative in four patients, and unknown in one patient. There was no correlation between the % mast cells in patients' bone marrows, or blood tryptase level, and the subtype of SM. The % of mast cells in the bone marrow in patients was 10% in 14, 10–20% in six, 25–35% in five, 40–65% in four, and >65% in four. Tryptase blood levels (n=32) were >200 ng/mL (upper limit of detection) in 11 patients, 20 ng/mL in five patients, 21–60 ng/mL in eight patients, 61–100 ng/mL in four patients, and 101–199 ng/mL in four patients. Testing for FIP1L1-PDGFR α yielded negative results in all patients with SM and HES/CEL.

Efficacy

Systemic mastocytosis—The overall response rate to dasatinib in patients with SM was 33% (11 of 33 patients treated). Two patients, one with SM-PMF (KIT-D816V-negative, FIP1L1-PDGFR α -negative, JAK2 V617F-positive; complex abnormalities on cytogenetic analysis [47,XY,+1,der(1;7)(q10;p10),+9]) and one with SM-CEL (KIT-D816V-negative,

FIP1L1-PDGFR α -negative, JAK2 V617F-negative, insufficient metaphases on cytogenetic analysis), achieved a complete response lasting for 5 and 16 months, respectively (Table 4). Specifically, in SM-PMF patient we recorded the elimination of SM but PMF persisted. In SM-CEL patient, on the other hand, the bone marrow completely normalized. Both patients started dasatinib therapy at 70 mg PO twice daily. Both patients had low tryptase level, abnormal WBC count differential, and anemia, and had failed prior therapy with erythropoietin. The patient with SM-PMF progressed to AML after 8 months on dasatinib therapy and died, while the patient with SM-CEL died, while off therapy due to intercurrent medical problems, after 18 months. Importantly, in the patient with SM-CEL, the cytogenetic analysis performed on the bone marrow done one year after the start of dasatinib therapy, while on therapy and in complete response and with normal bone marrow findings, revealed cytogenetic abnormality 46,XY,t(5;12)(q33;q13) in 9 of 20 analyzed cells. This is a cytogenetic abnormality known to involve the gene for PDGFR β on chromosome 5q33, sensitive to dasatinib, and therefore likely reason for a response in this patients.

Nine patients (six with ISM and three with ASM) had symptomatic improvement, as recorded by treating physicians. One patient with ISM was KIT-D816V-negative while others were positive; none had cytogenetic abnormality. The duration of symptomatic responses ranged from 3 to 18+ months and five responses were ongoing at the time of analysis. The types of improvements in symptoms related to SM included: improvement in rash, diarrhea, bone pain, headaches, itching, fatigue, shortness of breath, indigestion, and decrease or elimination of anaphylactic reactions. Although one patient with ASM had a reduction in the spleen size (from 7 to 1 cm below the left costal margin, on physical examination), this patient did not fulfill predetermined response criteria for ASM (Table 2B).

There were no significant, sustained (for at least 3 months) responses in blood tryptase levels and, with the exception of the two patients achieving complete response, there were no significant, sustained (evident at least in 2 consecutive bone marrow biopsies performed 3 months apart) responses in the percentage of bone marrow mast cells.

AML—One complete response was observed in an 80-year-old male with cytogenetic abnormality [+ 8] who had CD117 (i.e. KIT) expressed on 66% bone marrow blasts. Testing for a mutation in KIT gene was not performed. He previously achieved a short complete response with cytarabine and daunorubicin chemotherapy (Table 4). He relapsed on dasatinib therapy after 60 weeks (15 months). Eight patients had no response (four stopped therapy within the first month).

HES/CEL—One 48-year-old woman with HES, previously treated with imatinib without response, achieved a complete response (Table 4), with normalization of blood and bone marrow findings and disappearance of symptoms related to the disease (rash, indigestion/nausea/diarrhea, and shortness of breath). Tests for KIT-D816V and PDGFR α were negative. She relapsed after 58 weeks (14.5 months) while off therapy because of toxicity. Other patients did not respond (one stopped therapy within the first month).

Other chronic myeloid diseases—No objective clinical responses were observed among the patients with MDS and PMF.

Treatment received during study

The initial dose of dasatinib was administered as 70 mg twice daily to 58 patients and as 140 mg once daily to nine patients with SM (Table 5). The median number of treatment cycles administered ranged from <1 to 20. Dasatinib treatment was continued without dose modification in 38% of patients overall. Dose reduction by one level was required in 34% of patients and by two levels in 9% of patients. No patient received a dose escalation. Dasatinib was discontinued within the first month in 12 patients (due to toxicity in nine patients). The most common reasons for patients discontinuing the study after the first month of therapy were no response (N=17), toxicity (N=14), and disease progression (N=6).

Safety and tolerability

Treatment-related adverse events among the 67 patients included in the study are detailed in Table 6. No grade 4 adverse events were reported. The majority of adverse events were mild-moderate (CTC grade 1 or 2). Grade 3 adverse events were reported in all disease groups. Pleural effusion was the most common grade 3 adverse event, occurring in 7 of 67 patients overall (similar to prior experience with dasatinib in CML). Grade 3 non-hematologic adverse events occurring in the subgroup of patients with SM comprised headache (four cases), pain (three cases), dyspnea and pleural effusion (two cases each), ascites, fatigue, hyperuricemia, nausea/vomiting, palpitations, platelet levels, and hemorrhage (1 case each). There were two cases of grade 3 hematologic toxicity (low platelets or anemia) in patients with SM, with six cases overall. Twenty-three patients discontinued dasatinib therapy because of toxicity (nine stopped early and 14 discontinued after at least 1 month on treatment).

Discussion

This open-label phase 2 study was designed to determine the objective response rate to dasatinib in patients with Ph⁺ acute and chronic myeloid diseases. Disease-specific response criteria were used. The response rate to dasatinib in patients with SM was 33%, including two complete responses and nine patients with symptomatic improvement. Objective responses to dasatinib were also achieved in one AML and one HES patient (complete response in each), but not in those with MDS and MF. These data indicate that dasatinib benefits a proportion of SM patients, mainly by improving their symptoms.

Cytoreductive therapy is indicated for patients with ASM and selected patients with less aggressive forms of SM to control mast cell burden and improve quality of life. Interferon- α and cladribine have been beneficial in this setting. A phase 2 trial of interferon- α in 20 adult patients with SM resulted in seven (35%) partial responses and no major responses.⁴⁵ In another small study, 10 patients with SM with severe symptoms were treated with cladribine and all experienced symptomatic responses, and improvements in mast cell parameters (serum tryptase and urinary histamine metabolite excretion), but none achieved a complete response.⁴⁶ Lack of complete responses and relatively short duration of partial responses to

interferon- α and cladribine justify investigations of novel targeted therapies for SM. The first such agent, imatinib, was proven ineffective against KIT-D816V carrying mast cells. The failure of imatinib to inhibit cells expressing KIT-D816V²²²³ is probably because of an allosteric clash within the activation loop caused by the structural change at residue 816, which is key for maintaining the inactive conformation needed for imatinib binding. Preclinical data, on the other hand, have shown that dasatinib is active against the KIT-D816V mutation⁴⁴ at clinically achievable concentrations. Interestingly, KIT-D816Y-bearing cells were found to be 10-fold more sensitive to dasatinib than were KIT-D816V/F-carrying cells, suggesting that conformational changes within the KIT activation loop may also influence the inhibitory activity of dasatinib.⁴³ The broad spectrum of activity of dasatinib against many mutations of a given TK may override possible mutational resistance and increase efficacy, compared with other small molecule TK inhibitors that bind more specifically to a target (KIT in this case).⁴⁷ In the present study, 28 of 33 patients with SM were positive for KIT-D816V mutation. However, only 2 SM patients achieved a complete response, and both tested negative for the KIT-D816V mutation. This result is rather disappointing as our expectations for a significant reduction in the mast cell burden in these patients was high based on the pre-clinical results with dasatinib against cells carrying KIT-D816V mutation. We were particularly cautious to account, in our assessment of possible responses, for known variability in the percent mast cells (in the bone marrow), and tryptase level (in blood) in patient samples from time to time. We required a record of a sustained improvement in these parameters for a response to be assigned, and this did not happen in other SM patients.

The complete responses achieved with dasatinib were durable, lasting for 5 months in the patient with SM-MF and for 16 months in the patient with SM-CEL. Two other patients in the study achieved durable complete responses; 15 months in one patient with AML previously treated with intensive chemotherapy, and 14.5 months in one patient with HES previously treated with prednisone, imatinib, and hydroxyurea. The patient with SM-CEL exhibiting a complete response was found, on a later testing, to harbour a cytogenetic abnormality involving PDGFR β , a TK sensitive to dasatinib and likely responsible for a response in this patient. Molecular abnormalities possibly sensitive to dasatinib and responsible for responses in other patients achieving a complete response are currently unknown.

A further nine patients (six with ISM and three with ASM) had symptomatic improvement lasting for 3 to 18+ months. Patients with mast cell diseases can exhibit a myriad of symptoms, ranging in severity from bothersome to life-threatening. In this study, improvements were documented by treating physicians in terms of rash, diarrhea, bone pain, headaches, itching, fatigue, shortness of breath, indigestion, anaphylactic reactions, and spleen size. Symptom improvement is an important therapeutic goal for all forms of SM and can enhance patients' quality of life. However, our expectation was to observe significant elimination of mast cell burden in treated SM patients and, therefore, our evaluations during therapy focused on the bone marrow and blood (e.g. tryptase) testing, rather than on the proper documentation of symptom improvement. This is a limitation of our study.

Chronic therapy is required to maintain symptomatic responses in patients with SM and, therefore, tolerability is an important issue affecting treatment strategy. The safety profile of dasatinib has been well established in patients with Ph+ CML.³⁷³⁸³⁹⁴⁰ No new or unexpected adverse events emerged in patients with Ph- myeloid diseases treated with dasatinib in the present study. The majority of adverse events were mild-moderate and no grade 4 toxicities were observed. None of the patients discontinued therapy early because of toxicity. Grade 3 adverse events leading to dose interruption or dose reduction were observed in all disease subgroups. Grade 3 pleural effusions were reported in 10% of patients. Previous clinical studies of dasatinib have also reported pleural effusions, which can be managed by dose interruption and reduction, and with the administration of diuretics and steroids.⁴⁸⁴⁹ The majority of dose reductions were by one level, from 140 mg/day to 100 mg/day, administered as 50 mg twice daily or 100 mg once daily. Data from a dose optimization trial in patients with Ph+ CML have suggested that the incidence and severity of pleural effusions may be lower with dasatinib 100 mg administered once daily leading to a very recent change in the recommended starting dose for CML patients.⁵⁰ It is possible that the 100mg once daily starting dose in this trial would have resulted in less toxicity.

All of the patients achieving a complete response were initially treated with dasatinib 70 mg twice daily. Three of the four patients with a complete response required a dose reduction by one or two levels because of toxicity; one patient (with HES) stopped therapy due to toxicity and then relapsed. It is not possible to draw any conclusions from these preliminary data about potential differences in therapeutic ratio between once-daily and twice-daily schedules of dasatinib.

In conclusion, dasatinib therapy is beneficial in a proportion of SM patients, mainly by improving disease-related symptoms. However, dasatinib is associated with side-effects that may prevent desirable long-term therapeutic use of this agent for patients with SM. Dasatinib therapy does not seem to have significant activity in patients with AML, MDS, PMF, and HES/CEL.

Acknowledgments

Supported in part by **P30 CA016672**

Professional writing and editorial support provided by Tim Kelly and Andrew Richardson, funded by Bristol-Myers Squibb.

References

1. Deininger M, Buchdunger E, Drucker BJ. The development of imatinib as a therapeutic agent for chronic myeloid leukaemia. *Blood*. 2005; 105:2640–2653. [PubMed: 15618470]
2. Campbell PJ, Green AR. The myeloproliferative disorders. *N Engl J Med*. 2006; 355:2452–66. [PubMed: 17151367]
3. Valent P, Horny HP, Escribano L, et al. Diagnostic criteria and classification of mastocytosis: a consensus proposal. *Leuk Res*. 2001; 25:603–625. [PubMed: 11377686]
4. Valent P, Akin C, Sperr WR, et al. Diagnosis and treatment of systemic mastocytosis: state of the art. *Br J Haematol*. Sep; 2003 122(5):695–717. [PubMed: 12930381]
5. Yarden Y, Kuang WJ, Yang-Feng T, et al. Human proto-oncogene *c-kit*: a new cell surface receptor tyrosine kinase for an unidentified ligand. *EMBO J*. 1987; 6:3341–3351. [PubMed: 2448137]

6. Valent P, Spanblöchl E, Sperr WR, et al. Induction of differentiation of human mast cells from bone marrow and peripheral blood mononuclear cells by recombinant human stem cell factor/kit-ligand in long-term culture. *Blood*. 1992; 80:2237–2245. [PubMed: 1384799]
7. Wang B, Tsukada J, Higashi T, et al. Growth suppression of human mast cells expressing constitutively active c-kit receptors by JNK inhibitor SP600125. *Genes Cells*. 2006; 11:983–992. [PubMed: 16923120]
8. Furitsu T, Tsujimura T, Tono T, et al. Identification of mutations in the coding sequence of the proto-oncogene c-kit in a human mast cell leukemia cell line causing ligand-independent activation of c-kit product. *J Clin Invest*. 1993; 92:1736–1744. [PubMed: 7691885]
9. Nagata H, Worobec AS, Oh CK, et al. Identification of a point mutation in the catalytic domain of the protooncogene c-kit in peripheral blood mononuclear cells of patients who have mastocytosis with an associated hematologic disorder. *Proc Natl Acad Sci U S A*. Nov 7; 1995 92(23):10560–10564. [PubMed: 7479840]
10. Fritsche-Polanz R, Jordan JH, Feix A, et al. Mutation analysis of C-KIT in patients with myelodysplastic syndromes without mastocytosis and cases of systemic mastocytosis. *Br J Haematol*. May; 2001 113(2):357–364. [PubMed: 11380399]
11. Longley BJ, Tyrrell L, Lu SZ, et al. Somatic c-KIT activating mutation in urticaria pigmentosa and aggressive mastocytosis: establishment of clonality in a human mast cell neoplasm. *Nat Genet*. Mar; 1996 12(3):312–314. [PubMed: 8589724]
12. Paschka P, Marcucci G, Ruppert AS, et al. Adverse prognostic significance of KIT mutations in adult acute myeloid leukemia with inv(16) and t(8;21): a Cancer and Leukemia Group B Study. *J Clin Oncol*. 2006 Aug 20; 24(24):3904–11. [PubMed: 16921041]
13. Pardanani A, Ketterling RP, Li CY, et al. CHIC2 deletion, a surrogate for FIP1L1-PDGFRα fusion, occurs in systemic mastocytosis associated with eosinophilia and predicts response to imatinib mesylate therapy. *Blood*. Nov 1; 2003 102(9):3093–3096. [PubMed: 12842979]
14. Swolin B, Rodger S, Roupe G. Cytogenetic studies in patients with mastocytosis. *Cancer Genet Cytogenet*. Jul 15; 2000 120(2):131–135. [PubMed: 10942803]
15. Pardanani A, Brockman SR, Paternoster SF, et al. FIP1L1-PDGFRα fusion: prevalence and clinicopathologic correlates in 89 consecutive patients with moderate to severe eosinophilia. *Blood*. Nov 15; 2004 104(10):3038–3045. [PubMed: 15284118]
16. Gotlib J, Cools J, Malone JM 3rd, Schrier SL, Gilliland DG, Coutre SE. The FIP1L1-PDGFRα fusion tyrosine kinase in hypereosinophilic syndrome and chronic eosinophilic leukemia: implications for diagnosis, classification, and management. *Blood*. Apr 15; 2004 103(8):2879–2891. [PubMed: 15070659]
17. Griffin JH, Leung J, Bruner RJ, Caligiuri MA, Briesewitz R. Discovery of a fusion kinase in EOL-1 cells and idiopathic hypereosinophilic syndrome. *Proc Natl Acad Sci U S A*. Jun 24; 2003 100(13):7830–7835. [PubMed: 12808148]
18. Ostman A, Heldin CH. Involvement of platelet-derived growth factor in disease: development of specific antagonists. *Adv Cancer Res*. 2001; 80:1–38. [PubMed: 11034538]
19. Akin C, Brockow K, D'Ambrosio C, et al. Effects of tyrosine kinase inhibitor STI571 on human mast cells bearing wild-type or mutated c-kit. *Exp Hematol*. 2003; 31:686–692. [PubMed: 12901973]
20. Buchdunger E, Cioffi CL, Law N, et al. Abl protein-tyrosine kinase inhibitor STI571 inhibits in vitro signal transduction mediated by c-kit and platelet-derived growth factor receptors. *J Pharmacol Exp Ther*. 2000; 295:139–145. [PubMed: 10991971]
21. Zermati Y, De Sepulveda P, Féger F, et al. Effect of tyrosine kinase inhibitor STI571 on the kinase activity of wild-type and various mutated c-kit receptors found in mast cell neoplasms. *Oncogene*. 2003; 22:660–664. [PubMed: 12569358]
22. Frost M, Ferrao PT, Hughes TP, Ashman LK. Juxtamembrane mutant V560GK it is more sensitive to imatinib (STI571) compared with wild-type c-Kit whereas the kinase domain mutant D816VKit is resistant. *Mol Cancer Ther*. 2002; 1:1115–1124. [PubMed: 12481435]
23. Ma Y, Zeng S, Metcalfe DD, et al. The c-KIT mutation causing human mastocytosis is resistant to STI571 and other KIT kinase inhibitors; kinases with enzymatic site mutations show different

- inhibitor sensitivity profiles than wild-type kinases and those with regulatory type mutations. *Blood*. 2002; 99:1741–1744. [PubMed: 11861291]
24. Pardanani A, Elliott M, Reeder T, et al. Imatinib for systemic mast-cell disease. *Lancet*. 2003 Aug 16; 362(9383):535–6. [PubMed: 12932387]
  25. Droogendijk HJ, Kluin-Nelemans HJ, van Doormaal JJ, Oranje AP, van de Loosdrecht AA, van Daele PL. Imatinib mesylate in the treatment of systemic mastocytosis: a phase II trial. *Cancer*. 2006 Jul 15; 107(2):345–51. [PubMed: 16779792]
  26. Cortes J, Ault P, Koller C, Thomas D, Ferrajoli A, Wierda W. Efficacy of imatinib mesylate in the treatment of idiopathic hypereosinophilic syndrome. *Blood*. 2003 Jun 15; 101(12):4714–6. [PubMed: 12595304]
  27. Salem Z, Zalloua PA, Chehal A, et al. Effective treatment of hypereosinophilic syndrome with imatinib mesylate. *Hematol J*. 2003; 4(6):410–2. [PubMed: 14671612]
  28. Tashiro H, Shirasaki R, Noguchi M, Gotoh M, Kawasaki K, Shirafuji N. Molecular analysis of chronic eosinophilic leukemia with t(4;10) showing good response to imatinib mesylate. *Int J Hematol*. 2006 Jun; 83(5):433–8. [PubMed: 16787876]
  29. Hasselbalch HC, Bjerrum OW, Jensen BA, Clausen NT, Hansen PB, Birgens H. Imatinib mesylate in idiopathic and postpolycythemic myelofibrosis. *Am J Hematol*. 2003 Dec; 74(4):238–42. [PubMed: 14635203]
  30. Tefferi A, Mesa RA, Gray LA, et al. Phase 2 trial of imatinib mesylate in myelofibrosis with myeloid metaplasia. *Blood*. 2002 May 15; 99(10):3854–6. [PubMed: 11986248]
  31. David M, Cross NC, Burgstaller S, et al. Durable responses to imatinib in patients with PDGFRB fusion gene-positive and BCR-ABL-negative chronic myeloproliferative disorders. *Blood*. 2007 Jan 1; 109(1):61–4. [PubMed: 16960151]
  32. Jovanovic JV, Score J, Waghorn K, et al. Low-dose imatinib mesylate leads to rapid induction of major molecular responses and achievement of complete molecular remission in FIP1L1-PDGFR α -positive chronic eosinophilic leukemia. *Blood*. 2007 Jun 1; 109(11):4635–40. [PubMed: 17299092]
  33. Musto P, Falcone A, Sanpaolo G, Bodenizza C, Carella AM. Inefficacy of imatinib-mesylate in sporadic, aggressive systemic mastocytosis. *Leuk Res*. 2004; 28:421–422. [PubMed: 15109544]
  34. Quintas-Cardama A, Aribi A, Cortes J, Giles FJ, Kantarjian H, Verstovsek S. Novel approaches in the treatment of systemic mastocytosis. *Cancer*. 2006 Oct 1; 107(7):1429–39. [PubMed: 16948123]
  35. Kalac M, Quintas-Cardama A, Vrhovac R, Kantarjian H, Verstovsek S. A critical appraisal of conventional and investigational drug therapy in patients with hypereosinophilic syndrome and clonal eosinophilia. *Cancer*. 2007 Sep 1; 110(5):955–64. [PubMed: 17654661]
  36. Verstovsek S, Quintas-Cardama A, Kantarjian H, Tefferi A. Experimental therapy in myelofibrosis with myeloid metaplasia. *Expert Opin Investig Drugs*. 2006 Dec; 15(12):1555–63.
  37. Cortes J, Rousselot P, Kim DW, et al. Dasatinib induces complete hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in blast crisis. *Blood*. 2007; 109:3207–3213. [PubMed: 17185463]
  38. Guilhot F, Apperley J, Kim DW, et al. Dasatinib induces significant hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in accelerated phase. *Blood*. 2007; 109:4143–4150. [PubMed: 17264298]
  39. Hochhaus A, Kantarjian HM, Baccarani M, et al. Dasatinib induces notable hematologic and cytogenetic responses in chronic-phase chronic myeloid leukemia after failure of imatinib therapy. *Blood*. 2007; 109:2303–2309. [PubMed: 17138817]
  40. Kantarjian H, Pasquini R, Hamerschlak N, et al. Dasatinib or high-dose imatinib for chronic-phase chronic myeloid leukemia after failure of first-line imatinib: a randomized phase 2 trial. *Blood*. 2007; 109:5143–5150. [PubMed: 17317857]
  41. O'Hare T, Walters DK, Stoffregen EP, et al. In vitro activity of Bcr-Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutants. *Cancer Res*. 2005; 65:4500–4505. [PubMed: 15930265]
  42. Lombardo LJ, Lee FY, Chen P, et al. Discovery of N-(2-chloro-6-methyl-phenyl)-2-(6-(4-(2-hydroxyethyl)-piperazin-1-yl)-2-methylpyrimidin-4-ylamino)thiazole-5-carboxamide

- (BMS-354825), a dual Src/Abl kinase inhibitor with potent antitumor activity in preclinical assays. *J Med Chem.* 2004; 47:6658–6661. [PubMed: 15615512]
43. Schittenhelm MM, Shiraga S, Schroeder A, et al. Dasatinib (BMS-354825), a dual SRC/ABL kinase inhibitor, inhibits the kinase activity of wild-type, juxtamembrane, and activation loop mutant KIT isoforms associated with human malignancies. *Cancer Res.* 2006 Jan 1; 66(1):473–81. [PubMed: 16397263]
44. Shah NP, Lee FY, Luo R. Dasatinib (BMS-354825) inhibits KITD816V, an imatinib-resistant activating mutation that triggers neoplastic growth in most patients with systemic mastocytosis. *Blood.* 2006 Jul 1; 108(1):286–91. [PubMed: 16434489]
45. Casassus P, Caillat-Vigneron N, Martin A, et al. Treatment of adult systemic mastocytosis with interferon-alpha: results of a multicentre phase II trial on 20 patients. *Br J Haematol.* 2002 Dec; 119(4):1090–7. [PubMed: 12472593]
46. Kluin-Nelemans HC, Oldhoff JM, Van Doormaal JJ, et al. Cladribine therapy for systemic mastocytosis. *Blood.* 2003 Dec 15; 102(13):4270–6. [PubMed: 12933573]
47. Lee FY, Lombardo L, Camuso A, et al. BMS-354825 potently inhibits multiple selected oncogenic tyrosine kinases and possesses broad-spectrum antitumor activities in vitro and in vivo. *Proc Amer Assoc Cancer Res.* 2005; 46 Abstract 675.
48. Bergeron A, Réa D, Levy V, et al. Lung abnormalities after dasatinib treatment for chronic myeloid leukemia: a case series. *Am J Respir Crit Care Med.* 2007; 176:814–8. [PubMed: 17600277]
49. Quintás-Cardama A, Kantarjian H, O'Brien S, et al. Pleural effusion in patients with chronic myelogenous leukemia treated with dasatinib after imatinib failure. *J Clin Oncol.* 2007; 25:3908–3914. [PubMed: 17761974]
50. Shah NP, Kim DW, Kantarjian HM, et al. Dasatinib 50 mg or 70 mg BID compared to 100 mg or 140 mg QD in patients with CML in chronic phase (CP) who are resistant or intolerant to imatinib: One-year results of CA180034. *J Clin Oncol.* 2007; 25(Suppl 18S):358S. abstract 7004.

Table 1

Dose modification levels for dasatinib.

Dose level	Dose (mg) twice daily	Single daily dose (mg)
Escalation 1	100	200
Starting dose	70	140
Reduction 1	50	100
Reduction 2	40	80
Reduction 3	20	40

Table 2A

Response criteria.

Disease	Response criteria
ASM [*]	Major response: complete resolution of at least one clinical finding [C-Finding(s)] and no progression in other C-Findings • Complete remission = disappearance of mast cell infiltrates in affected organs, decrease of serum tryptase levels to <20 ng/ml, and disappearance of SM-associated organomegaly • Incomplete remission = decrease in mast cell infiltrates in affected organs and/or substantial decrease of serum tryptase level and/or visible regression of organomegaly • Pure clinical response = without decrease in mast cell infiltrates, without decrease in tryptase levels, and without regression of organomegaly. Partial Response: incomplete regression of one or more C-Finding(s) without complete regression and without progress in other C-Findings • Good partial response: >50% regression • Minor response: 50% regression. No response: C-Finding(s) persistent or progressive • Stable disease: C-Finding-parameters show constant range • Progressive disease: one or more C-Finding(s) show progression
AML and MDS	Complete remission: normalization of the peripheral blood and bone marrow with 5% blasts; normo- or hypercellular marrow; ANC > $1.0 \times 10^9/L$, and platelet count > $100 \times 10^9/L$. Partial Remission: as complete remission except for the presence of 6–25% marrow blasts, but reduction by >50%. Complete remission marrow: As complete remission but platelet count < $100 \times 10^9/L$. All other responses were considered failures.
PMF and CMML	Complete response: absence of signs or symptoms of the disease. WBC between 1 to $10 \times 10^9/L$ with no peripheral blasts, promyelocytes, or myelocytes and with normalization of bone marrow (< 5% blasts in normocellular or hypercellular marrow) for at least 4 weeks. Resolution of pretreatment cytopenias: • ANC $1.0 \times 10^9/L$ without G-CSF or GM-CSF • Hb 12.0 g/dL (11.0 g/dL for females) without erythropoietin or transfusion support • Platelets $100 \times 10^9/L$ without growth factor or transfusion support. Resolution of pretreatment leukocytosis and/or thrombocytosis: • WBC $10 \times 10^9/L$ without peripheral blasts, promyelocytes, or myelocytes • Platelets $100 \times 10^9/L$ but < $450 \times 10^9/L$. Partial response: improvement of two or more of the following: • ANC: – Increase by 100% and to above $10^9/L$ for neutropenia – WBC between $1-10 \times 10^9/L$ with persistence of immature cells (blasts, promyelocytes, myelocytes, metamyelocytes) for pretreatment leukocytosis. • Hb:

Disease	Response criteria
	Increase by 2 g/dL if it was below 10 g/dL Decrease in transfusion requirements by at least 50% (decrease in frequency and/or volume) Platelet count: - Below that level prior to therapy - Persistent thrombocytosis > 450 × 10⁹/L but < 50% of pretreatment Marrow blasts: - Reduction of marrow blasts to 5% or less if it was above 10% in normocellular or hypercellular marrow Organomegaly: - Reduction in splenomegaly and/or hepatomegaly by 50% of pretreatment dimensions (measured as length below the left costal margin on palpation) confirmed by imaging in difficult cases. • All other responses were considered failures.
HES/CEL	Complete response = disappearance of eosinophilia (> 10%) and disappearance of signs and symptoms of disease. Partial response = reduction of eosinophilia by > 50%; reduction of organomegaly by > 50%.

Abbreviations: AML = acute myeloid leukemia; ANC = absolute neutrophil count; CMML = chronic myelomonocytic leukemia; G-CSF = granulocyte colony-stimulating factor; GM-CSF = granulocyte-macrophage colony-stimulating factor; Hb = haemoglobin; Hct = hematocrit; HES = hypereosinophilic syndrome; CEL = chronic eosinophilic leukaemia; MDS = myelodysplastic syndromes; PMF = primary myelofibrosis; ASM = aggressive systemic mastocytosis; WBC = white blood cell count

* Response criteria for ISM and SM-AHNMD have not been established and are descriptive

Table 2B

Definition of responses in C-Findings, for patients with ASM

C-Finding	MR (100%)	GPR (>50%)
Bone marrow/blood ANC $<1.0 \times 10^9/L$ Anemia, Hb <10 g/dL Thrombocytopenia (plt $<100 \times 10^9/L$)	ANC $>1.0 \times 10^9/L$ Hb >10 g/dL Plt $>100 \times 10^9/L$	Decrease below 1000 reverted by $>50\%$ ^a [e.g. 600–800 = 50%] Decrease below 10 reverted by $>50\%$ ^b Decrease to $<100,000$ ^c reverted by 50%
Liver Hepatomegaly with ascites	No ascites	Decrease of frequency of paracenteses
Abnormal liver tests Elevated enzyme levels Hypoalbuminemia Portal hypertension	Decrease to normal Increase to normal Normal vein pressure	Increase reverted by $>50\%$ Decrease reverted by $>50\%$ Increase in vein pressure improved by 50%
Spleen Palpable splenomegaly with hypertension—thrombocytopenia	No signs of hypertension, plt $>100 \times 10^9/L$	Parameters indicating hypertension, plt improved by $>50\%$
GI-tract Malabsorption with hypoalbuminemia and/or weight loss	Normal albumin Normal weight	Decrease in albumin improved by $>50\%$ Weight loss reverted by $>50\%$
Bones Huge osteolyses or/and severe osteoporosis with pathologic fractures	No osteolyses, normal bone density	Partial resolution of osteolyses, decreased bone density reverted by 50%

MR Major response: GPR, good partial response.

^a A minimum increase of 0.1×10^9 ANC/L blood is required.^b A minimum increase of 1 g/dL HB is required.^c A minimum increase of 10×10^9 platelets/L blood is required for GPR.

Table 3

Baseline demographic and clinical characteristics by patient diagnosis.

	SM	AML	MDS/CMML	HES	CEL	PMF
N	33 (9 ASM, 18 ISM, 6 SM-AHNMD ^a)	9	6 (3 MDS, 3 CMML)	5	3	11
Median age (range) (years)	57 (29–74)	70 (57–91)	68 (61–75)	48 (23–71)	68 (62–75)	63 (43–77)
Sex (M:F)	14:19	7:2	4:2	3:2	2:1	10:1
Cytogenetics	Diploid: 30 Complex (3 abn): 1 Unknown: 2 ^b	Diploid: 5 +(8): 1 -(7): 1 Other: 2 ^c	Diploid: 5 +(8): 0 -(7): 0 Other: 1 ^d	Diploid: 5	Diploid: 0 +(8): 1 Complex (3 abn): 1 Other: 1 ^e	Diploid: 9 Complex (3 abn): 2
PS						
0	0	1	2	2	0	1
1	31	7	4	2	2	8
2	2	1	0	1	1	2
Number of prior therapies						
0	16	1	3	0	1	2
1	12	2	1	4	0	4
2	4	4	1	0	1	3
3	0	2	0	1	1	1
4	1	0	1	0	0	1
Prior therapies (number of patients)	Inatinib (8); denileukin diftiox (4); interferon (3); darbepoetin (4); cladribine (4); 17-AAG (1); PKC412 (1)	Idarubicin+cytarabine (5); fludarabine+cytarabine; high-dose cytarabine; cytarabine+tipifarnib; allo BMT; VNP40101M; perfosine; sapacitabine; thalidomide; azacitidine; hydroxyurea	Peg-IFN, lenalidomide, PTK787 + inatinib; thalidomide; decitabine (2); hydroxyurea; clofarabine + cytarabine	Inatinib (2); peg-IFN (1); nilotinib (1)	Epoetin (1); Hydroxyurea (1); idarubicin + cytarabine (1); decitabine + valproic acid (1); inatinib (1)	PTK787 (3); lenalidomide (2); interferon, thalidomide; etanercept, inatinib, RAD001, hydroxyurea (5); azacitidine (3); peg-IFN, anagrelide

^aCEL (1), MF (1), MDS/MPD (1), CMML (3);^bInsufficient metaphase;

Author Manuscript

Author Manuscript

Author Manuscript

Author Manuscript

20q- & i(17q),
d₁(11p)
e₁(5;12)(q31;p13)
Abbreviations: Abn=abnormalities; Allo BMT = allogeneic bone marrow transplantation; AML = acute myeloid leukemia; ASM = aggressive systemic mastocytosis; CEL = chronic eosinophilic leukemia;
CMML = chronic myelomonocytic leukemia; HES = hypereosinophilic syndrome; ISM = indolent systemic mastocytosis; MDS = myelodysplastic syndromes; PMF = primary myelofibrosis; MPD =
myeloproliferative disease; Peg-IFN = pegylated interferon alfa. SM = systemic mastocytosis with associated hematopoietic clonal non-mast cell disease; 17-AAG =
17-(allylamino)-17-demethoxygeldanamycin

Table 4

Complete responses to dasatinib.

	SM			AML	HES
	SM-PMF		SM-CEL		
Patient characteristics	61-year-old white male, diagnosed with SM-PMF in 6/2005 Anemia, SOB, fatigue, back pain		64-year-old African American male, diagnosed with SM-CEL in 9/2005 Anemia, SOB, fatigue, low-grade fever, sweating, loss of weight	80-year-old white male, diagnosed with AML in 11/2005	48-year-old white female, diagnosed with HES in 1/2001 Rash, SOB, diarrhea, fatigue
Prior therapy	Darbepoetin x 5 months without result		Epoetin alfa x 4 months without result	Daunorubicin + cytarabine with short complete response (1 month)	Prednisone, imatinib, hydroxyurea
Baseline laboratory values	Hb: 9.4 g/dL Pit: $90 \times 10^9/L$ WBC: $4.4 \times 10^9/L$ 6% blasts Tryptase 22 ng/mL		Hb: 9.4 g/dL Pit: $150 \times 10^9/L$ WBC: $8.3 \times 10^9/L$ Eos: 13%, AEC: $1.08 \times 10^9/L$ Tryptase 13 ng/mL	Hb: 11.8 g/dL Pit: $604 \times 10^9/L$ WBC: $6.9 \times 10^9/L$ No blasts	Hb 13.3 g/dL Pit: $299 \times 10^9/L$ WBC: $9.4 \times 10^9/L$ Eos: 28%, AEC: $2.63 \times 10^9/L$
Baseline BM, cytogenetics, and gene analysis	4% blasts 10–15% MC on biopsy Reticulin 2+ (scale 0–3) Cyto: 47, XY, +1, der(1;7)(q10;p10), +9 [10/20] KIT-D816V-negative JAK2-V617F-positive		20% Eos 10–20% MC on biopsy; insufficient metaphases on cyto analysis, but t(5;12)(q33;q13) after one year of therapy KIT-D816V-negative, PDGFR α -negative, JAK2-V617F-negative	13% blasts Cyto: +8 [2/20]	20% Eos Diploid cytogenetics KIT-D816V-negative PDGFR α -negative
Dasatinib dose	70 mg twice daily		70 mg twice daily; –1 level due to pleural effusion; –2 level due to fatigue	70 mg twice daily; –1 level due to rash; –2 level due to rash	70 mg twice daily; –1 level due to nausea/vomiting, headache and rash; stopped therapy due to pleural effusion
Response to dasatinib	Starting at 3 weeks: Pit: $148 \times 10^9/L$ Starting at 6 months: Hb: 10.1 g/dL BM at 3 and 6 months: Hypocellular No SM Reticulin 4+ Blasts 4%		Starting at 2 months: Hb: 13.0 g/dL WBC: $7.4 \times 10^9/L$ Eos: 3.9% BM at 3, 6, 9, 12, and 15 months: Eos 4% No SM Normal cellularity	At 2 months: BM: 3% blasts Normal cyto Hb: 13.7 g/dL Pit: $223 \times 10^9/L$ WBC: $6 \times 10^9/L$	Starting at 1 week: 4% Eos in blood At 3, 6, and 12 months: 4% Eos in BM
Outcome	Died after 8 months due to AML		Died off therapy (due to other medical reasons) after 18 months	Cytogenetic relapse after 6 months (+8 [16/20]); AML relapse after 15 months (BM: 10% blasts)	Relapsed after 14.5 months while off therapy

Abbreviations: AEC = absolute eosinophil count; AML = acute myeloid leukemia; BM = bone marrow; CEL = chronic eosinophilic leukemia; Cyto = cytogenetics; Eos = eosinophils; Hb = hemoglobin level; HES = hypereosinophilic syndrome; MC = mast cells; PMF = primary myelofibrosis; Pit = platelet count; SM = systemic mastocytosis; SOB = shortness of breath; WBC = white blood cell count

Table 5

Summary of dasatinib treatment received, dose modifications, and discontinuations.

	SM (N=33)	AML (N=9)	MDS/CMML (N=6)	HES (N=5)	CEL (N=3)	PMF (N=11)
Initial dose schedule (N)						
70 mg twice daily	24	9	6	5	3	11
140 mg once daily	9					
Median number of treatment cycles (range)	4 (1–20)	1 (1–18)	1 (1–2)	3 (0–17)	3 (1–4)	6 (1–19)
No. of dose modifications						
0	11	2	2	2	2	7
–1	13	2	2	2	1	3
–2	5	1				
Early (<1 month) discontinuation of therapy (N)	4 (toxicity)	4 (toxicity 2, progression 1, death 1)	2 (toxicity 1, comorbid condition 1)	1 (toxicity)		1 (toxicity)
Off-study due to (N):						
Relapse	4	1				
Progression	0	2	2	1	1	
Toxicity	6	2	2	2	1	1
Death	2	1	1			
No response	16	3	1	2	1	10

Table 6

Treatment-related adverse events.

Adverse event	Grade 1	Grade 2	Grade 3
Anorexia	1	1	
Ascites			1
Atrial fibrillation			1
Confusion		1	
Diarrhea	3	2	
Dysphagia	1		
Dyspepsia	1		
Dyspnea	4	11	3
Edema	1	4	
Fatigue	1	4	3
Fever	1		
Flushing	1	2	
Headache	4	3	5
Hemorrhage			1
Hyperuricemia			1
Nausea/vomiting	9	9	3
Pain	2	2	3
Palpitations	1		1
Pericardial effusion	1		
Platelets/hemoglobin			6
Pleural effusion	1	6	7
Pleural pain		1	
Pulmonary edema	1	1	
Rash	1	3	
Tachycardia	1		
Tinnitus		1	
Urticaria	1	1	

Author Manuscript

Author Manuscript

Author Manuscript

Author Manuscript

Adverse event	Grade 1	Grade 2	Grade 3
Weight gain	2		
Weight loss	1		